PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
9 October 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE ANGEL CAPITAL
ASSOCIATION SOUTH EAST REGIONAL CONFERENCE IN SAVANNAH GA
(Charlottesville, VA, October 09, 2008) – PluroGen Therapeutics, Inc. today announced it was selected and
presented as 1 of only 8 companies at the Angel Capital Association South East Regional Conference 2008
in Savannah GA.
Neal G. Koller, President & CEO of PluroGen, made the presentation to an audience of angel network
investors from around the country. Commenting on the presentation, Mr. Koller said “PluroGen is honored
to be selected for this presentation. They had many companies applying with only a few slots available.
Our selection underlines the quality of investment PluroGen offers and validates PluroGen’s opportunity for
investor return.”
About PluroGen Therapeutics, Inc.
PluroGen is a skin care wound healing company commercializing its core patent-protected gel technology
platform that provides superior and differentiated physical, bio-impact and multi-function benefits. Our
multiple technology platforms are configurable to deliver drug and non-drug compounds as protected and
advanced therapeutic and topical products for simple and complex skin care, burn and wound healing.
PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of treatment in tissue
management and healing (cleansing, infection, pain, inflammation, tissue salvage, tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially in skin and wound cleansing products and for two
branded topical antimicrobial products, PluroGel™ Barrier Gels and PluroGel™ Barrier Dressings. PluroGel™
technology is currently in routine use at the University of Virginia Medical Center, having shown superior
results on more than 2,000 patients in two different patient populations, severe burns and chronic
wounds. The PluroGen management and operational teams, Boards and Principal Investigators are
recognized global clinical and commercial leaders in PluroGen’s target markets of burn and wound care and
in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About the Angel Capital Association
As of March, 2008 the Angel Capital Association has 144 member angel groups and another 18
organization as affiliates throughout North America. These angel groups: (1) Fund approximately 700
new companies each year, and have an on-going portfolio of more than 5,000 entrepreneurial companies
throughout the United States and Canada; (2) Have as their members about 6,000 high-net-worth
individuals, all of whom are “accredited investors” under SEC guidelines, with a net worth of at least $1
million, an annual income of at least $200,000, or both. Many, if not most, have a net worth many times
that minimum requirement; (3) These individuals also serve on thousands of other public and private
boards. For example, one group in the Northeast, CommonAngels, has 67 members who currently serve
on the board of directors of over 160 companies, including 19 public, 77 private and 65 non-profit
companies; in the past, they have served on over 400 boards, including 58 public, 217 private and 134
non-profit.
For more information about the Angel Capital Association visit their web site at www.angelcapitalassociation.org.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise
President & CEO
9 October 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE ANGEL CAPITAL
ASSOCIATION SOUTH EAST REGIONAL CONFERENCE IN SAVANNAH GA
(Charlottesville, VA, October 09, 2008) – PluroGen Therapeutics, Inc. today announced it was selected and
presented as 1 of only 8 companies at the Angel Capital Association South East Regional Conference 2008
in Savannah GA.
Neal G. Koller, President & CEO of PluroGen, made the presentation to an audience of angel network
investors from around the country. Commenting on the presentation, Mr. Koller said “PluroGen is honored
to be selected for this presentation. They had many companies applying with only a few slots available.
Our selection underlines the quality of investment PluroGen offers and validates PluroGen’s opportunity for
investor return.”
About PluroGen Therapeutics, Inc.
PluroGen is a skin care wound healing company commercializing its core patent-protected gel technology
platform that provides superior and differentiated physical, bio-impact and multi-function benefits. Our
multiple technology platforms are configurable to deliver drug and non-drug compounds as protected and
advanced therapeutic and topical products for simple and complex skin care, burn and wound healing.
PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of treatment in tissue
management and healing (cleansing, infection, pain, inflammation, tissue salvage, tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially in skin and wound cleansing products and for two
branded topical antimicrobial products, PluroGel™ Barrier Gels and PluroGel™ Barrier Dressings. PluroGel™
technology is currently in routine use at the University of Virginia Medical Center, having shown superior
results on more than 2,000 patients in two different patient populations, severe burns and chronic
wounds. The PluroGen management and operational teams, Boards and Principal Investigators are
recognized global clinical and commercial leaders in PluroGen’s target markets of burn and wound care and
in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About the Angel Capital Association
As of March, 2008 the Angel Capital Association has 144 member angel groups and another 18
organization as affiliates throughout North America. These angel groups: (1) Fund approximately 700
new companies each year, and have an on-going portfolio of more than 5,000 entrepreneurial companies
throughout the United States and Canada; (2) Have as their members about 6,000 high-net-worth
individuals, all of whom are “accredited investors” under SEC guidelines, with a net worth of at least $1
million, an annual income of at least $200,000, or both. Many, if not most, have a net worth many times
that minimum requirement; (3) These individuals also serve on thousands of other public and private
boards. For example, one group in the Northeast, CommonAngels, has 67 members who currently serve
on the board of directors of over 160 companies, including 19 public, 77 private and 65 non-profit
companies; in the past, they have served on over 400 boards, including 58 public, 217 private and 134
non-profit.
For more information about the Angel Capital Association visit their web site at www.angelcapitalassociation.org.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise